Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MPI | P34949 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11955245 | 0.81 | ERN1 (0.42) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL15941609 | 0.76 | CYP1A2 (0.57) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL32662668 | 0.75 | ALDH1A1 (0.66) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL6509 | 0.75 | ALDH1A1 (0.66) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL3939862 | 0.74 | CYP1A2 (0.48) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL29707567 | 0.74 | CYP1A2 (0.64) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL4196895 | 0.74 | CYP1A2 (0.64) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL27883300 | 0.73 | KDM4E (0.33) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL31633210 | 0.72 | CYP1A2 (0.47) | ALDH1A1KDM4EMEN1MAPTMPI | |
| SCHEMBL2113974 | 0.72 | KDM4E (0.33) | ALDH1A1KDM4EMEN1MAPTMPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101622242-B | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG | 2013-07-17 | — | — | CN | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8410275-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2012-09-06 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-8232403-B2 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2012-07-31 | — | — | US | disclosed |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-04-19 | — | — | US | disclosed |
| EP-2432784-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011058109-A1 | FUSED BICYCLIC PYRROLE AND IMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058112-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011058111-A1 | AMINOPURINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2011-05-19 | — | — | WO | disclosed |
| WO-2010133836-A1 | FUSED BICYCLIC PYRAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-11-25 | — | — | WO | disclosed |
| CN-101622242-A | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG | 2010-01-06 | — | — | CN | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2009-09-10 | — | — | US | disclosed |
| EP-2024356-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | Novartis AG (CH) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007128568-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | NOVARTIS AG (CH) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227580-A1 | Bicyclic derivatives as CETP inhibitors | CETP, LCAT, CES1 | ALDH1A1 3563/4885KDM4E 1621/4885MEN1 4636/4885 |
| US-20120095005-A1 | Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors | PI4KA, PDPK1, PIK3CA | ALDH1A1 1059/4885KDM4E 3834/4885MEN1 3999/4885 |
| US-20120225874-A1 | BICYCLIC DERIVATIVES AS CETP INHIBITORS | CETP, LCAT, CES1 | ALDH1A1 3563/4885KDM4E 1621/4885MEN1 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.